89Zr is an emerging radionuclide that plays an essential role in immuno-positron emission
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

Purpose Almost all radiolabellings of antibodies with 89 Zr currently employ the hexadentate
chelator desferrioxamine (DFO). However, DFO can lead to unwanted uptake of 89 Zr in …

Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or
antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is …

The use of 89Zr-antibody PET imaging to measure antibody biodistribution and tissue
pharmacokinetics is well established, but current PET systems lack the sensitivity needed to …

The identification of molecular drivers of disease and the compelling rise of biotherapeutics
have impacted clinical care but have also come with challenges. Such therapeutics include …

Purpose Currently, the most commonly used chelator for labelling antibodies with 89 Zr for
immunoPET is desferrioxamine B (DFO). However, preclinical studies have shown that the …

The thermodynamic stability of a metal–ligand complex, as measured by the formation
constant (log β), is one of the most important parameters that determines metal ion selectivity …

Hydroxypyridinones (HOPOs) form outstanding building blocks for the development of a
variety of agents in the field of metal chelation. The pyridinone ring is easily synthesized and …

Diagnostic molecular images, obtained by positron emission tomography (PET), have
successfully functioned as sensitive tools for detecting and monitoring the treatment of …